ENSC
vs
S&P 500
ENSC
S&P 500
Over the past 12 months, ENSC has underperformed S&P 500, delivering a return of -93% compared to the S&P 500's +12% growth.
Stocks Performance
ENSC vs S&P 500
Performance Gap
ENSC vs S&P 500
Performance By Year
ENSC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ensysce Biosciences Inc
Glance View
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California. The company went IPO on 2017-12-01. The firm is engaged in the development of small and large molecule drug delivery platforms targeting pain and cancer markets. Ensysce’s products include PF614 and PF614- Multi-Pill Abuse Resistant (MPAR). PF614 is a Trypsin-Activated Abuse Protection (TAAP) oxycodone prodrug that is a biologically inactive compound which can be metabolized in the body to produce a drug with demonstrable features aimed at resisting both oral and non-oral modes of prescription drug abuse. TAAP technology seeks to remove the ability of a user to abuse PF614 intravenously or intra-nasally. PF614-MPAR is a combination product of PF614 and nafamostat has designed to limit abuse potential by providing resistance to use through injection or inhalation and to provide overdose protection against excessive oral ingestion. Ensysce initiated a Phase I clinical trial for PF614-MPAR to evaluate safety and Pharmacokinetics in healthy.
